About Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition affecting approximately 17.5 million infants, adolescents and adults in the U.S. It is characterized by intense
itching and is caused by both inflammation and a breakdown of the skins barrier function. Activation of LXR in skin keratinocytes, the most common cell type in the outer layer of skin, has been shown to increase the formation of corneocytes
and the production of lamellar lipids. LXR activation also has been shown to have an anti-inflammatory effect in skin equivalent to a high potency corticosteroid.
About Allergan plc
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic
products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye
care, medical aesthetics and dermatology, gastroenterology, womens health, urology and anti-infective therapeutic categories.
Allergan is an
industry leader in Open Science, the Companys R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest
development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Companys success is powered
by our more than 15,000 global colleagues commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what it is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver
innovative and meaningful treatments that help people around the world live healthier lives every day.
For more information, visit Allergans
website at www.Allergan.com.
Allergan Cautionary Statement Regarding Forward-Looking Statements
Statements contained in this press release that refer to future events or other non-historical facts, including with respect to Allergans acquisition of
Vitae, are forward-looking statements that reflect Allergans current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update
these forward-looking statements. Actual results may differ materially from Allergans current expectations depending upon a number of factors affecting Allergans business. These factors include, among others, the difficulty of predicting
the timing or outcome of FDA approvals or actions, if any; successful integration of the Vitae acquisition and the ability to recognize the anticipated synergies and benefits of the Vitae acquisition; the anticipated size of the markets and
anticipated demand for Vitaes products; the impact of competitive products and pricing; market acceptance of and continued demand for Allergans and Vitaes products; difficulties or delays in manufacturing; and other risks and
uncertainties detailed in Allergans periodic public filings with the Securities and Exchange Commission, including but not limited to Allergans Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on
Form 10-Q for the quarter ended June 30, 2016 (such periodic public filings having been filed under the Actavis plc name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these